Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

143.75 +1.55 (+1.09%)

Delayed Quote Updated: 3:28 PM EDT, Oct 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

26 27 Next >

Axsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp Volatility ↗

Today 9:44 EDT

Axsome's steady ascent has flipped the script—it now outpaces Moderna in quarterly revenue despite starting from a fraction of its size.

Via The Motley Fool

2 Growth Stocks to Hold for the Next Decade (Hint: These Aren’t AI Stocks) ↗

October 23, 2026

These drugmakers are capitalizing on their pipeline successes.

Via The Motley Fool

Topics Artificial Intelligence

2 Under-the-Radar Stocks to Buy and Hold ↗

October 16, 2026

They aren’t the best-known corporations in the biotech industry, but they can deliver excellent long-term returns.

Via The Motley Fool

Topics Artificial Intelligence

Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's? ↗

October 12, 2026

Auvelity's Alzheimer's expansion could transform Axsome by 2030.

Via The Motley Fool

Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026? ↗

October 07, 2026

Axsome is posting 65% revenue growth but burning cash, while Moderna's vaccine market is cooling yet its oncology pipeline carries transformative potential.

Via The Motley Fool

Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2

October 07, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? ↗

October 01, 2026

Vertex dominates cystic fibrosis with expanding disease coverage and a pipeline entering new therapeutic areas. Axsome is building a commercial drug portfolio quickly but is still working toward...

Via The Motley Fool

Topics Intellectual Property

Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day

September 21, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Sees AUVELITY Prescriptions Accelerate as Alzheimer’s Launch Gains Traction ↗

September 19, 2026

Axsome Therapeutics (NASDAQ:AXSM) executives said the company is seeing accelerating prescription growth for AUVELITY following its sales-force expansion and the recent launch of the drug in...

Via MarketBeat

Axsome Therapeutics Highlights Auvelity Growth, Pipeline Progress at H.C. Wainwright Conference ↗

September 19, 2026

Axsome Therapeutics (NASDAQ:AXSM) executives highlighted growth across its commercial portfolio, an expanded sales force and multiple late-stage clinical programs during the H.C. Wainwright 28th Annual...

Via MarketBeat

Analysts Think Axsome Therapeutics Stock Could Soar 35% Over the Next 12 Months. Is the Stock a No-Brainer Buy? ↗

September 18, 2026

Or are its best days in the rearview mirror?

Via The Motley Fool

Axsome Therapeutics vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 18, 2026

One company is growing a commercial drug business with limited margin for error on the path to profitability. The other has a platform that proved itself at global scale and keeps finding new diseases...

Via The Motley Fool

Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 18, 2026

Axsome is generating revenue from approved drugs but missing estimates and widening losses. Revolution Medicines just changed the standard of care for one of the deadliest cancers in existence.

Via The Motley Fool

Is Axsome Therapeutics a Buy on the Dip? ↗

September 18, 2026

The stock slipped about 15% over the past three months.

Via The Motley Fool

Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026

September 17, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 11, 2026

One company is scaling revenue rapidly but burning cash; the other is pioneering gene therapy with minimal sales and massive losses.

Via The Motley Fool

Topics Intellectual Property

Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 10, 2026

Axsome is already selling drugs with 65% revenue growth, while Viking bets on obesity treatments still in trials, a classic choice between proven sales and blockbuster potential.

Via The Motley Fool

Topics Intellectual Property

Axsome Therapeutics to Participate in Upcoming Investor Conferences

September 02, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation

August 31, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗

August 29, 2026

Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable.

Via The Motley Fool

Axsome Therapeutics Stock Is Up 16% Year to Date. Why Wall Street Thinks It Has Even More Room to Run ↗

August 23, 2026

The company has also crushed broader equities over the past five years.

Via The Motley Fool

Here’s How Much You Would Have Made Owning Axsome Therapeutics Stock In The Last 5 Years ↗

August 17, 2026

Axsome Therapeutics (NASDAQ:AXSM) has outperformed the market over the past 5 years by 46.84% on an annualized basis producing an average annual return of 58.59%. Currently, Axsome Therapeutics has a...

Via Benzinga

If You Invested $100 In Axsome Therapeutics Stock 10 Years Ago, You Would Have This Much Today ↗

August 13, 2026

Axsome Therapeutics (NASDAQ:AXSM) has outperformed the market over the past 10 years by 26.64% on an annualized basis producing an average annual return of 40.19%. Currently, Axsome Therapeutics has a...

Via Benzinga

Axsome Therapeutics Analysts Increase Their Forecasts Following Q2 Results ↗

August 11, 2026

Axsome Therapeutics (NASDAQ:AXSM) reported Q2 losses of 99 cents per share and sales of $218.4 million, missing analyst estimates. Analysts have mixed price targets for the stock.

Via Benzinga

Axsome Therapeutics Q2 Earnings Call Highlights ↗

August 10, 2026

Axsome Therapeutics (NASDAQ:AXSM) reported second-quarter 2026 net product revenue of $218 million, up 46% from a year earlier, as sales of AUVELITY and SUNOSI increased and prescription demand for...

Via MarketBeat

Topics Earnings

Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

August 10, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Prediction: These 2 Stocks Will Keep Winning No Matter What the Market Does ↗

August 04, 2026

These innovative biotech companies should reap the benefits of their breakthroughs.

Via The Motley Fool

Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy

July 15, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10

July 14, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

3 Under-the-Radar Stocks to Buy and Hold ↗

July 10, 2026

Sometimes, little-known stocks are worth buying.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

26 27 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.